DOP2014000221A - Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek - Google Patents
Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mekInfo
- Publication number
- DOP2014000221A DOP2014000221A DO2014000221A DO2014000221A DOP2014000221A DO P2014000221 A DOP2014000221 A DO P2014000221A DO 2014000221 A DO2014000221 A DO 2014000221A DO 2014000221 A DO2014000221 A DO 2014000221A DO P2014000221 A DOP2014000221 A DO P2014000221A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- inhibitor
- methods
- mek
- treat cancer
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos de tratamiento de pacientes con cáncer, en donde los métodos comprenden administrar al paciente una cantidad eficaz de un inhibidor de MEK y una cantidad eficaz de un inhibidor de PI3K. Se describen también composiciones en las que se combinan los inhibidores de MEK y PI3K.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261621252P | 2012-04-06 | 2012-04-06 | |
FR1351158 | 2013-02-12 | ||
US201361771457P | 2013-03-01 | 2013-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2014000221A true DOP2014000221A (es) | 2014-12-15 |
Family
ID=49301040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2014000221A DOP2014000221A (es) | 2012-04-06 | 2014-10-01 | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150031882A1 (es) |
EP (1) | EP2854854A1 (es) |
JP (1) | JP2015515476A (es) |
KR (1) | KR20150003786A (es) |
CN (1) | CN104334192A (es) |
AU (1) | AU2013243429A1 (es) |
CA (1) | CA2869152A1 (es) |
CL (1) | CL2014002668A1 (es) |
CO (1) | CO7121349A2 (es) |
CR (1) | CR20140480A (es) |
DO (1) | DOP2014000221A (es) |
EA (1) | EA201491836A1 (es) |
MX (1) | MX2014012001A (es) |
PE (1) | PE20142020A1 (es) |
PH (1) | PH12014502219A1 (es) |
SG (1) | SG11201406199TA (es) |
TN (1) | TN2014000418A1 (es) |
WO (1) | WO2013152165A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3082957B1 (en) * | 2013-12-20 | 2022-04-06 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
EP3363911A4 (en) * | 2015-10-14 | 2019-04-03 | Nitto Boseki Co., Ltd | METHOD FOR DETERMINING HUMAN SENSITIVE CELLULAR LINES TO A MEDICINE BY A METHOD OF ANALYSIS USING A MEASUREMENT OF THE ACTIVITY OF TWO TYPES OF PROTEIN KINASE |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065358B (zh) | 2004-10-20 | 2015-03-11 | 默克雪兰诺有限公司 | 3-芳基氨基吡啶衍生物 |
WO2007044729A2 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007044813A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
CA2776944A1 (en) * | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
-
2013
- 2013-04-04 JP JP2015504716A patent/JP2015515476A/ja active Pending
- 2013-04-04 WO PCT/US2013/035231 patent/WO2013152165A1/en active Application Filing
- 2013-04-04 PE PE2014001533A patent/PE20142020A1/es not_active Application Discontinuation
- 2013-04-04 SG SG11201406199TA patent/SG11201406199TA/en unknown
- 2013-04-04 CN CN201380029317.1A patent/CN104334192A/zh active Pending
- 2013-04-04 MX MX2014012001A patent/MX2014012001A/es unknown
- 2013-04-04 EA EA201491836A patent/EA201491836A1/ru unknown
- 2013-04-04 CA CA2869152A patent/CA2869152A1/en not_active Abandoned
- 2013-04-04 KR KR20147030877A patent/KR20150003786A/ko not_active Application Discontinuation
- 2013-04-04 AU AU2013243429A patent/AU2013243429A1/en not_active Abandoned
- 2013-04-04 EP EP13717123.7A patent/EP2854854A1/en not_active Withdrawn
-
2014
- 2014-10-01 DO DO2014000221A patent/DOP2014000221A/es unknown
- 2014-10-01 PH PH12014502219A patent/PH12014502219A1/en unknown
- 2014-10-02 US US14/504,970 patent/US20150031882A1/en not_active Abandoned
- 2014-10-02 TN TN2014000418A patent/TN2014000418A1/fr unknown
- 2014-10-03 CL CL2014002668A patent/CL2014002668A1/es unknown
- 2014-10-16 CR CR20140480A patent/CR20140480A/es unknown
- 2014-10-29 CO CO14239743A patent/CO7121349A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20150003786A (ko) | 2015-01-09 |
AU2013243429A1 (en) | 2014-10-23 |
CO7121349A2 (es) | 2014-11-20 |
EA201491836A1 (ru) | 2015-02-27 |
PE20142020A1 (es) | 2014-12-24 |
CN104334192A (zh) | 2015-02-04 |
WO2013152165A1 (en) | 2013-10-10 |
CR20140480A (es) | 2014-11-17 |
CA2869152A1 (en) | 2013-10-10 |
TN2014000418A1 (en) | 2016-03-30 |
PH12014502219A1 (en) | 2015-01-12 |
MX2014012001A (es) | 2015-05-11 |
CL2014002668A1 (es) | 2015-01-16 |
SG11201406199TA (en) | 2014-10-30 |
EP2854854A1 (en) | 2015-04-08 |
US20150031882A1 (en) | 2015-01-29 |
JP2015515476A (ja) | 2015-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
CL2015002807A1 (es) | Terapia de combinación | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
ECSP14013244A (es) | COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
NI201300052A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
GT201300148A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
DOP2017000174A (es) | Terapias de combinación para el tratamiento de cánceres | |
DOP2009000132A (es) | Inhibidores de la actividad de la akt |